Cytosorbents (CTSO) Common Equity (2010 - 2026)

Cytosorbents has reported Common Equity for 17 years, with the latest figure at $2.2 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 84.91% year-over-year to $2.2 million; the trailing twelve-month figure through Mar 2026 stood at $2.2 million (down 84.91% YoY), and the FY2025 full-year result was $5.9 million, down 46.85% from the prior year.
• Common Equity for Q1 2026 stood at $2.2 million, down from $5.9 million in the prior quarter.
• The five-year high for Common Equity was $55.4 million in Q1 2022, with the low at $2.2 million in Q1 2026.
• Historically, Common Equity has averaged $22.3 million across 5 years, with a median of $18.8 million in 2023.
• Annual changes were most pronounced in 2025 — Common Equity fell 25.89% — and 2026, when it sank 84.91%.
• Cytosorbents' Common Equity stood at $35.4 million in 2022, then slumped by 33.63% to $23.5 million in 2023, then plunged by 52.7% to $11.1 million in 2024, then plunged by 46.85% to $5.9 million in 2025, then tumbled by 62.83% to $2.2 million in 2026.
• The last three Common Equity figures came in at $2.2 million (Q1 2026), $5.9 million (Q4 2025), and $9.0 million (Q3 2025), per Business Quant data.